A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-Controlled,Phase 3 Efficacy and Safety Study of Benralizumab (MEDI-353) to Reduce Oral Corticosteroid Use in Patients with Uncontrolled Asthma on High Dose Inhaled Corticosteroid plus Long-

Project: Other project

StatusFinished
Effective start/end date7/15/1412/31/16

Funding

  • AstraZeneca LP: $5,557.71